Edition:
United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

297.40DKK
7:54am EST
Change (% chg)

kr.1.40 (+0.47%)
Prev Close
kr.296.00
Open
kr.297.60
Day's High
kr.298.10
Day's Low
kr.295.50
Volume
68,911
Avg. Vol
341,211
52-wk High
kr.305.80
52-wk Low
kr.202.80

LUN.CO

Chart for LUN.CO

About

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and... (more)

Overall

Beta: 0.64
Market Cap(Mil.): kr.58,495.44
Shares Outstanding(Mil.): 197.62
Dividend: --
Yield (%): --

Financials

  LUN.CO Industry Sector
P/E (TTM): 202.20 29.93 30.76
EPS (TTM): 1.46 -- --
ROI: 2.16 15.46 14.89
ROE: 3.19 16.64 16.30

BRIEF-Lundbeck: board member buys 15,000 shares at DKK 242.01

* Board member Lars Holmqvist purchased on Nov. 7 total of 15,000 Lundbeck shares at 242.01 Danish crowns ($36)

Nov 07 2016

UPDATE 2-Lundbeck highlights turnaround with upgraded profit forecast

* Shares up 8 pct (Adds detail, CEO quotes, updates share price)

Nov 02 2016

Lundbeck raises its 2016 revenue and profit forecasts

COPENHAGEN, Nov 2 Danish pharmaceutical group lifted its full-year revenue and operating profit forecasts after posting a better than expected quarterly result.

Nov 02 2016

BRIEF-Lundbeck: FDA approves Carnexiv injection

* U.S. FDA approves Carnexiv (Carbamazepine) injection as intravenous replacement therapy for oral carbamazepine formulations

Oct 10 2016

BRIEF-Ligand says partner Lundbeck plans to make Carnexiv commercially available in U.S. in early 2017

* Partner Lundbeck receives FDA approval of Carnexiv(tm) (carbamazepine) injection as intravenous short-term replacement therapy for certain seizure types

Oct 07 2016

European shares retreat after Fed-inspired rally; Lundbeck slumps

* Lundbeck slumps after study failure (ADVISORY- Follow European and UK stock markets in real time on the Reuters Live Markets blog on Eikon - see cpurl://apps.cp./cms/?pageId=livemarkets) Adds details, updates prices)

Sep 23 2016

European shares pull back after Fed-inspired rally; Lundbeck slumps

MILAN, Sept 23 European shares fell in early trading on Friday, pulling back from two-week highs hit in the previous session following the U.S. Federal Reserve's decision to push back on its next rate increase.

Sep 23 2016

Lundbeck says Alzheimer's drug fails in late-stage study

Danish drugmaker H Lundbeck A/S's highly anticipated experimental Alzheimer's drug failed in a late-stage study, underscoring the challenges faced by drugmakers to tackle the debilitating memory-robbing disease.

Sep 22 2016

UPDATE 2-Lundbeck says Alzheimer's drug fails in late-stage study

Sept 22 Danish drugmaker H Lundbeck A/S's highly anticipated experimental Alzheimer's drug failed in a late-stage study, underscoring the challenges faced by drugmakers to tackle the debilitating memory-robbing disease.

Sep 22 2016

BRIEF-Lundbeck says alzheimer's drug late stage study fails

* Conclusions from first out of three phase 3 studies on idalopirdine in alzheimer's disease

Sep 22 2016

Earnings vs. Estimates